STC 1010
Alternative Names: STC-1010Latest Information Update: 10 Jul 2026
At a glance
- Originator Brenus Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Tumour cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Colorectal cancer
- No development reported Gastrointestinal cancer; Pancreatic cancer
Most Recent Events
- 17 Apr 2026 Updated efficacy and adverse events data from the phase I/IIa BreAK CRC trial in Colorectal cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 14 Apr 2026 Efficacy data from a phase I/IIa BreAK CRC trial in Colorectal cancer released by Brenus Pharma
- 19 Feb 2026 Pharmacodynamics data from preclinical trials in Colorectal cancer released by Brenus Pharma